Artia Global Partners LP Acquires Shares of 20,811 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Artia Global Partners LP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,811 shares of the company's stock, valued at approximately $1,152,000. Artia Global Partners LP owned about 0.05% of Tarsus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. acquired a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $25,000. R Squared Ltd acquired a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $53,000. HighTower Advisors LLC purchased a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $207,000. Summit Investment Advisors Inc. increased its position in shares of Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after acquiring an additional 244 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $223,000. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TARS shares. Guggenheim lifted their price objective on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday. Jefferies Financial Group boosted their price target on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Barclays dropped their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. HC Wainwright reiterated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $64.67.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 7,131 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $330,093.99. Following the completion of the sale, the chief executive officer now directly owns 70,720 shares of the company's stock, valued at $3,273,628.80. The trade was a 9.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dianne C. Whitfield sold 2,137 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now directly owns 46,355 shares in the company, valued at $2,322,849.05. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock worth $1,581,173 in the last three months. Company insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Price Performance

NASDAQ TARS traded down $3.08 during trading hours on Friday, reaching $47.22. The company's stock had a trading volume of 537,648 shares, compared to its average volume of 693,775. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The company's 50-day moving average is $47.82 and its two-hundred day moving average is $48.67. The stock has a market cap of $1.81 billion, a PE ratio of -12.47 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.